Ettrix

Etoricoxib

Acute & chronic symptomatic treatment of OA & RA. Ankylosing spondylitis (AS); acute gouty arthritis & pain eg, primary dysmenorrhoea & minor dental procedures. 60 mg: Chronic low back pain.

OA 30 or 60 mg once daily. Not to exceed 60 mg daily. RA & AS 60 mg once daily, may be increased to max: 90 mg once daily. Chronic low back pain Not to exceed 60 mg once daily. Acute pain & gouty arthritis, primary dysmenorrhoea Not to exceed 120 mg once daily for 8 days. Minor dental procedures Not to exceed 90 mg once daily for 8 days. Mild hepatic insufficiency (Child-Pugh score 5-6) Not to exceed 60 mg once daily. Moderate hepatic insufficiency (Child-Pugh score 7-9) Not to exceed 60 mg every other day.

May be taken with or without food.

Hypersensitivity. CHF (NYHA II-IV); established ischemic heart disease, peripheral arterial disease &/or cerebrovascular disease including patients recently undergone CABG surgery or angioplasty; increased risk of CV disease eg, ischaemic heart disease & stroke; uncontrolled HTN. Pregnancy.

Discontinue use at 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity; persistent abnormal LFTs are detected. Not a substitute for aspirin in CV prophylaxis. Serious skin reactions eg, exfoliative dermatitis, SJS & TEN. Increased risk of GI ulceration, bleeding & perforation; thrombotic events eg, MI, stroke. History of serious GI events & other risk factors associated w/ PUD eg, alcoholism, smoking, corticosteroid therapy. Risk factors for heart disease, HTN, hyperlipidemia, diabetes; preexisting edema or heart failure; acute asthmatic attacks, urticaria or rhinitis; cardiac dysfunction. Ensure adequate hydration prior to therapy. Closely monitor BP during therapy. May mask fever. Long-term use. Monitor renal function in patients w/ preexisting significant renal impairment, uncompensated heart failure or cirrhosis. Not recommended in advanced renal disease. Hepatic or renal dysfunction. Not recommended in women of childbearing potential. Lactation. Elderly ≥65 yr, debilitated patients.

Abdominal pain. Alveolar osteitis; oedema/fluid retention; dizziness, headache; palpitations, arrhythmia; HTN; bronchospasm; constipation, flatulence, gastritis, heartburn/acid reflux, diarrhea, dyspepsia/epigastric discomfort, nausea, vomiting, oesophagitis, oral ulcer; increased ALT & AST; ecchymosis; asthenia/fatigue, flu-like disease.

Increased prothrombin time INR w/ warfarin. Decreased plasma AUC w/ rifampin. Monitor for MTX-related toxicity. Diminished antihypertensive effects of diuretics, ACE inhibitors, AIIAs. Increased plasma lithium levels. Increased rate of GI ulceration or other complications w/ low-dose aspirin.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

B